This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Boston Scientific Schedule Of Major Presentations At The American College Of Cardiology 2013

NATICK, Mass., March 4, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 62nd Annual Scientific Session of the American College of Cardiology which takes place March 9-11 in San Francisco, California. The clinical presentations will provide new insights on Boston Scientific research in cardiovascular disease, including aortic valve disease and atrial fibrillation.

Schedule of EventsAll programs are Pacific Standard Time with events held at the Moscone Center.

Saturday, March 9

  • PREVAIL Late Breaking Clinical Trial Results: David R. Holmes Jr., M.D., Mayo Clinic, Rochester, Minn., will present the acute procedural safety results of the PREVAIL clinical trial that evaluates the WATCHMAN® left atrial appendage closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy. PREVAIL is a confirmatory trial on the safety and efficacy of the WATCHMAN device. Results will be presented at 9:10 a.m. in South, Esplanade Ballroom.
  • PLATINUM Vessel Straightening Analysis: Jeffrey J. Popma, M.D., Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass., will present the results of the PLATINUM vessel straightening analysis, designed to evaluate the impact of stent design on native vessel distortion following coronary artery stenting in severely angulated lesions.  Results will be presented at 10:00 a.m. in the Poster Session area, Expo North.

Sunday, March 10

  • PLATINUM Three-Year Clinical Trial Results:  Ian T. Meredith, M.B.B.S., Ph.D. MonashHeart, Southern Health, Monash Medical Center, Clayton, Victoria, Australia, will present the three-year data of the PLATINUM Workhorse clinical trial. Two year follow-up of this trial confirmed the safety and efficacy of the platinum chromium PROMUS Element™ Plus Stent System, which uses the combination of the market-leading everolimus drug and fluorinated copolymer. Results will be presented at 8:15 a.m. in West, Room 2001.

Monday, March 11

  • REPRISE I Feasibility Study:  Ian T. Meredith, M.B.B.S., Ph.D. MonashHeart, Southern Health, Monash Medical Center, Clayton, Victoria, Australia, will present six-month study results of the differentiated second generation Lotus Aortic Valve Replacement System.  REPRISE I was designed as a feasibility study with a primary endpoint of clinical procedural success. Results will be presented at 9:15 a.m. in West, Room 2009.   

Conference attendees are invited to visit Boston Scientific and "Technologies that transform tomorrow and Products that perform today" at booth N5933.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs